Pharmaceutical Research

, Volume 25, Issue 4, pp 727–739

Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products: An Overview of the PQRI Recommendations

  • Daniel L. Norwood
  • Diane Paskiet
  • Michael Ruberto
  • Thomas Feinberg
  • Alan Schroeder
  • Guirag Poochikian
  • Qingxi Wang
  • Tian Jing Deng
  • Fran DeGrazio
  • Melinda K. Munos
  • Lee M. Nagao
Commentary

Abstract

The Product Quality Research Institute Leachables and Extractables Working Group includes pharmaceutical development scientists representing industry, government, and academia. The Working Group was created and constituted to address scientific and regulatory questions concerning the pharmaceutical development process for Orally Inhaled and Nasal Drug Products (OINDP) related to organic extractables and leachables. This effort has resulted in the creation of a detailed “Recommendation Document”, which was submitted to the U.S. FDA for consideration in September 2006. The recommendations include proposed safety and analytical thresholds for leachables and extractables, as well as detailed “best practice” recommendations for various aspects of the OINDP pharmaceutical development process, including: materials selection for OINDP container closure system components, Controlled Extraction Studies, Leachables Studies, and Routine Extractables Testing. The Working Group’s processes and the detailed and comprehensive recommendations that resulted from those processes, demonstrate that the Product Quality Research Institute collaborative process can result in consensus science-based and data driven recommendations that could have a positive effect on patient care. It is anticipated that the Working Group’s recommendations will also contribute to the new “Quality by Design” pharmaceutical development paradigm. This commentary summarizes the best practice recommendations within the context of an overall pharmaceutical development process.

Key words

controlled extraction studies leachables OINDP pharmaceutical development PQRI 

References

  1. 1.
    D. Ball, J. Blanchard, D. Jacobson-Kram, R. McClellan, T. McGovern, D. L. Norwood, M. Vogel, R. Wolff, and L. Nagao. Development of safety qualification thresholds and their use in drug product evaluation. Toxicol. Sci. 97(2):226–236 (2007).PubMedCrossRefGoogle Scholar
  2. 2.
    IPAC-RS. Good manufacturing practices guideline for suppliers of components for orally inhaled and nasal drug products. International Pharmaceutical Aerosol Consortium on Regulation and Science(2006).Google Scholar
  3. 3.
    D. L. Norwood. Understanding the challenges of extractables and leachables for the pharmaceutical industry—safety and regulatory environment for pharmaceuticals. Am. Pharm. Rev. 10(2):32–39 (2007).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Daniel L. Norwood
    • 1
  • Diane Paskiet
    • 2
  • Michael Ruberto
    • 3
  • Thomas Feinberg
    • 4
  • Alan Schroeder
    • 5
  • Guirag Poochikian
    • 5
    • 6
  • Qingxi Wang
    • 7
  • Tian Jing Deng
    • 8
    • 9
  • Fran DeGrazio
    • 10
  • Melinda K. Munos
    • 11
  • Lee M. Nagao
    • 11
  1. 1.Boehringer Ingelheim Pharmaceuticals, Inc.RidgefieldUSA
  2. 2.West Monarch Analytical LaboratoriesMaumeeUSA
  3. 3.Ciba Expert ServicesTarrytownUSA
  4. 4.Catalent Pharma Solutions, Inc.Research Triangle ParkUSA
  5. 5.U.S. Food and Drug AdministrationCenter for Drug Evaluation and ResearchSilver SpringUSA
  6. 6.Poochikian Pharma ConsultingRockvilleUSA
  7. 7.Merck & Co., Inc.West PointUSA
  8. 8.Pharmaceutical Product Development, Inc.MadisonUSA
  9. 9.BioDuro Inc.San DiegoUSA
  10. 10.West Pharmaceutical ServicesLionvilleUSA
  11. 11.Drinker, Biddle, and Reath, LLPWashingtonUSA

Personalised recommendations